News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Pluristem Life Systems Inc. To Present At The 10th Annual Meeting Of The International Society for Cellular Therapy (ISCT), Dublin, Ireland

10/19/2005 5:11:05 PM

HAIFA, Israel--(BUSINESS WIRE)--April 28, 2004--Pluristem Life Systems, Inc. -- (OTCBB:PLRS), a biotechnology company dedicated to the expansion of stem cells from umbilical cord blood to address a myriad of fatal illnesses, today announced that the Company has been chosen to present at the 10th Annual Meeting of The International Society for Cellular Therapy (ISCT) that will be held in Dublin, Ireland on May 7-10, 2004.

Pluristem will present laboratory results demonstrating the significant superiority of three-dimensional (3-D) cultures over the conventional two-dimensional (2-D) cultures presently used in most stem cell expansion research. The results confirm the unique quality and potential of Pluristem's proprietary 3-D PluriX(TM) bioreactor.

Pluristem's core technology is designed to expand hematopoietic stem cells from umbilical cord blood for bone marrow transplantations using its proprietary PluriX(TM) bioreactor system. The uniqueness of the PluriX(TM) bioreactor is its ability to create a 3-D microenvironment that closely resembles the structure and function of the body's bone marrow environment. The PluriX(TM) bioreactor, consisting of a stromal cell culture, provides an optimal environment to support and maintain hematopoietic stem cells (HSC). These vital early stage stem cells have the distinct capacity to self-renew, expand and differentiate or evolve into different types of blood cells. They are exclusively required for bone marrow transplants and are the only cells that can reconstitute the hematopoietic system following bone marrow transplantation.

Bone marrow transplants (BMT) offer an ultimate treatment for many blood and immune system diseases. Today BMT using cord blood have achieved limited success due to the small volume of blood that can be collected from the umbilical cord. As recently announced, the PluriX(TM) bioreactor can produce from one donation of HSC from cord blood sufficient quantities for a number of adult transplants.

"We are honored to once again be chosen to present at an international forum of our esteemed peers. As Pluristem moves into the final stage of pre-clinical trials, this exposure can strengthen our alliances and exposure within the scientific community as well as create opportunities for future technology and business collaborations," stated Dr. Irit Arbel, CEO.

About ISCT

The ISCT is a professional organization for those working or interested in cell-based research, processing, manipulation and clinical translation. The ISCT serves as a global forum and voice for clinicians, scientists, regulatory and laboratory personnel, and other parties engaged or interested in basic research and development, translational studies, and the clinical application of all cellular based therapies.

About Pluristem

Pluristem is a biotechnology company dedicated to the development of stem cell expansion technology. The Company is concentrating on the expansion of cord blood hematopoietic stem cells (blood and immune system cells) to provide vital stem cell expansion services to blood banks and transplants centers in the U.S. and Europe.

Safe Harbor Statement

Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing stem cell technology into a useful product which, among other things, can treat fatal illnesses and obtaining patent protection in the US and worldwide for our technology. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to complete its obligations under the stem cell license agreement, inability to finance the planned development of the technology, unforeseen technical difficulties in developing the stem cell technology, and challenges to or failure of our patent applications, which could among other things, delay or prevent product release or our ability to protect our products from competition. For further risk factors see the Company's 10-KSB filed with the SEC for our latest completed fiscal year.


for Pluristem Life Systems, Inc. DeMonte Associates Cynthia DeMonte, 212-605-0525

Read at

comments powered by Disqus